
Halitosis...
Primer Blog "específico" de Marketing Farmacéutico para países de habla hispana.
El presidente de Venezuela, Hugo Chávez, ha ordenado ocupar Orpin Farma Laboratorios, con sede en la ciudad de Guarenas, ubicada en el estado de Miranda (norte), por violar la legislación del país iberoamericano.
Según ha explicado, la empresa estaba prácticamente inactiva desde mediados de 2009, debido a la falta de insumos para elaborar sus productos. Además, sus trabajadores habían denunciado el impago de sus salarios.
"Empresa que esté abandonada por sus dueños o que no pague a sus empleados, tenemos que proceder a ocuparla aplicando la Constitución", ha dicho Chávez, en una intervención telefónica con Venezolana de Televisión (VTV), recogida por el diario 'El Nacional'.
En este sentido, ha instado a los 130 trabajadores de la empresa a sumarse al "proceso de evaluación y reactivación de la producción", ya que "cuentan con todo el apoyo de la clase obrera y del pueblo venezolano".
El líder socialista ha explicado que las instalaciones de la farmacéutica se utilizarán ahora para producir "fluidos y suministros tempranos para los hospitales del país", informa la Agencia Venezolana de Noticias (AVN).
VerUNITED from 7 Billion Actions on Vimeo.
“UNITED” -- PART 2 PALENQUE, COLOMBIA from 7 Billion Actions on Vimeo.
Ver también:
Abbott is said to have reached an agreement that would see the firm pay around $800 million for civil claims and about $500 million in criminal penalties, according to sources speaking to Bloomberg. (Ver)
Novartis AG, Europe’s second-biggest pharmaceutical company, plans to eliminate 2,000 jobs in Switzerland and the U.S. to offset the effect of reductions in drug prices.
The cuts will be implemented over three to five years, and Novartis will create 700 new positions in low-cost and other countries, the Basel, Switzerland-based company said in a statement today. Novartis plans to close a plant in Nyon, Switzerland, that makes over-the-counter drugs and chemical sites in Basel and Torre, Italy. The company will take a fourth- quarter restructuring charge of about $300 million.
“These actions are necessary to ensure that we adapt our organization to continue delivering on our mission of bringing innovative new drugs to patients,” Joe Jimenez, Novartis’s chief executive officer, said in the statement. (Más)
También en
About 1,100 jobs will go in Switzerland, and the other 900 will be lost in the USA. The losses will be offset by 700 new positions "in low cost and other countries", notably China and India.
A group of Harvard global health activists staged a protest Friday in front of Merck’s laboratory near the Harvard Medical School to urge the drug company to provide discounted HIV and AIDS medicine to poor countries.
The protest was billed as a “pool party demonstration”—replete with beach balls, an inflatable pool, and students in swim trunks—to demand that Merck “jump into the pool,” a reference to the Medicine Patent Pool.
The Medicine Patent Pool is an organization that negotiates deals with drug companies to ensure the availability in low-income and middle-income countries of discounted medicine to fight the human immunodeficiency virus. In many of these countries, drugs to fight the disease are far too expensive to be affordable to ordinary individuals. The deals struck by the Medicine Patent Pool seek to reduce costs while also attempting to ensure that the companies are minimally impacted by the discounts.
Imagen: Visual representation of the voice of the health community, ManchesterWhy a Medicines Patent Pool?
The Medicines Patent Pool was created in response to the threat that crucial sources of affordable HIV medicines were drying up. This is due to increased global pharmaceutical patenting required by countries’ membership in the World Trade Organization (WTO). When a medicine is patented in a specific country, it prevents anyone but the patent holder from producing and selling it, usually for a patent term of 20 years. This creates a monopoly situation, where it is possible to charge the highest price for medicines that a market can bear because there are no competitors. And people who can not afford such prices – particularly those who live in developing countries – are left empty-handed. A World Health Organization action plan that looks, among other things, at the relationship between patents and access to medicines, indicated that patent pools would be one way to address the lack of access to affordable and adapted medicines in developing countries.
Roche Holding AG will maintain a strategy of “targeted acquisitions” and isn’t seeking a mega- merger, Chief Executive Officer Severin Schwan said in comments that may rule out a bid for Abbott Laboratories’ prescription- drug spinoff.
“We’ve focused on smaller, bolt-on acquisitions,” Schwan said in an interview today in Frankfurt when asked whether an acquisition of a portion of Abbott’s business is attractive. “That’s how I see us continuing in our M&A strategy. We are not interested in mega-mergers. We are interested in very targeted acquisitions which complement our technologies and portfolios.
“Dum loquimur,
fugerit in vida aetas:
CARPE DIEM
quam minimum credula postero”
“Mientras hablamos,
habrá huido celosa la edad:
goza a bocados del momento,
confía lo menos posible
en el mañana”